InvestorsHub Logo
Followers 3
Posts 182
Boards Moderated 0
Alias Born 09/15/2013

Re: None

Thursday, 10/15/2015 7:22:16 AM

Thursday, October 15, 2015 7:22:16 AM

Post# of 5006
RXi Pharmaceuticals Gets Postive Review for Scar Revision Treatment - Shares Jumping 16% Pre-Market

10/15/15, 7:09 AM
07:09 AM EDT, 10/15/2015 (MT Newswires) -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company that owns a broad intellectual property portfolio including a unique self-delivering RNAi platform, said results from a blinded panel and an investigator review show that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PHIO News